The European Investment Bank signed on 25 June an €120 million loan agreement with Almirall, S.A. to support its research and development activities related to skin health care therapeutic products.
The implementation of the project will seek new pharmaceutical responses to pathologies such as psoriasis, atopic dermatitis and actinic keratosis, a type of precancerous cutaneous lesion....

This story is part of New Europe's Premium content.

To Read the Full Story, Subscribe or Sign In from the ↑ Top of the Page ↑
new europe join now